Manuscripts
Showing 1521 manuscripts.
High Prevalence of Tuberculosis Infection and Disease in Child Household Contacts of Adults With Rifampin-resistant Tuberculosis.
Citation
Kim S, Wu X, Hughes MD, Upton C, Narunsky K, Mendoza-Ticona A, Khajenoori S, Gonzales P, Badal-Faesen S, Shenje J, Omoz-Oarhe A, Rouzier V, Garcia-Prats AJ, Demers AM, Naini L, Smith E, Churchyard G, Swindells S, Shah NS, Gupta A, Hesseling AC, ACTG A5300/IMPAACT 2003/PHOENix Feasibility Study Team. High Prevalence of Tuberculosis Infection and Disease in Child Household Contacts of Adults With Rifampin-resistant Tuberculosis.. Pediatric Infectious Disease Journal. 2022. 41: 194-202. PMID: 35239624Journal
Pediatric Infectious Disease Journal
Study
IMPAACT 2003/ACTG 5300
Growth deficits in antiretroviral and HIV-exposed uninfected versus unexposed children in Malawi and Uganda persist through 60 months of age.
Citation
Fowler MG, Aizire J, Sikorskii A, Atuhaire P, Ogwang LW, Mutebe A, Katumbi C, Maliwichi L, Familiar I, Taha T, Boivin MJ, PROMISE-NEURODEV study team. Growth deficits in antiretroviral and HIV-exposed uninfected versus unexposed children in Malawi and Uganda persist through 60 months of age.. AIDS. 2022. 36: 573-582. PMID: 34750297Journal
AIDS
Impact of CYP2B6 Genotype, TB Therapy and Formulation on Efavirenz Pharmacokinetics in Infants and Children Under 40 Months of Age
Citation
Mina Nikanjam, Lana Tran, Ellen G. Chadwick , Mutsa Bwakura-Dangarembizi, Carolyn Bolton Moore, Pearl Samson, Stephen A Spector, Nahida Chakhtoura, Patrick Jean-Philippe, Lisa Frenkel, Bonnie Zimmer, Alex Benns, Jennifer Libous, Edmund V. Capparelli. Impact of CYP2B6 Genotype, TB Therapy and Formulation on Efavirenz Pharmacokinetics in Infants and Children Under 40 Months of Age. AIDS. 2022. 36: 525-532. PMID: 34873089Journal
AIDS
Study
P1070
Pharmacokinetics of Atazanavir Boosted With Cobicistat in Pregnant and Postpartum Women With HIV
Citation
Jeremiah D Momper, Jiajia Wang, Alice Stek, David E Shapiro, Kathleen M Powis, Kathleen Powis, Mary E Paul, Martina L Badell, Renee Browning, Nahida Chakhtoura, Kayla Denson, Kittipong Rungruengthanakit, Kathleen George, Edmund V Capparelli, Mark Mirochnick, Brookie M Best, IMPAACT P1026s Protocol Team. Pharmacokinetics of Atazanavir Boosted With Cobicistat in Pregnant and Postpartum Women With HIV. Journal of Acquired Immune Deficiency Syndromes. 2022. 89: 303-309. PMID: 34732682Journal
Journal of Acquired Immune Deficiency Syndromes
Study
P1026S
Exploring the value of Mycobacterium tuberculosis modified lipoprotein as a potential biomarker for TB detection in children
Citation
Xinxin Yang, Matthew F Wipperman, Sharon Nachman, Nicole S Sampson. Exploring the value of Mycobacterium tuberculosis modified lipoprotein as a potential biomarker for TB detection in children. BMC Infectious Diseases. 2022. 22: 158. PMID: 35177035Journal
BMC Infectious Diseases
Study
P1041
Emergence of Resistance in HIV-1 Integrase With Dolutegravir Treatment in a Pediatric Population From the IMPAACT P1093 Study
Citation
Cindy Vavro, Theodore Ruel, Andrew Wiznia, Nicole MontaƱez, Keith Nangle, Joseph Horton, Ann Buchanan, Eugene Stewart, Paul Palumbo. Emergence of Resistance in HIV-1 Integrase With Dolutegravir Treatment in a Pediatric Population From the IMPAACT P1093 Study. Antimicrobial Agents and Chemotherapy. 2022. 66: e0164521. PMID: 34694878Journal
Antimicrobial Agents and Chemotherapy
Study
P1093
Abacavir dosing in neonates from birth to 3 months of life: a population pharmacokinetic modelling and simulation study
Citation
Adrie Bekker, Edmund V. Capparelli, Avy Violari, Mark F. Cotton, Mae Cababasay, Jiajia Wang, Ruth Mathiba, Lubbe Wiesner, Andrew Wiznia, Pearl Samson, Renee Browning, Jack Moye, Firdose L. Nakwa, Bobbie Graham, Eric Decloedt, Helena Rabie, Mark Mirochnick, Tim R. Cressey, IMPAACT P1106 team. Abacavir dosing in neonates from birth to 3 months of life: a population pharmacokinetic modelling and simulation study. Lancet HIV. 2022. PMID: 27936233Journal
Lancet HIV
Study
P1106
Interactions between etonogestrel-releasing contraceptive implant and 3 antiretroviral regimens
Citation
Regis Kreitchmann, Alice Stek, Brookie M Best, Edmund Capparelli, Jiajia Wang, David Shapiro, Nahida Chakhtoura, Mark Mirochnick, Ahizechukwu C Eke, IMPAACT P1026s protocol team. Interactions between etonogestrel-releasing contraceptive implant and 3 antiretroviral regimens. Contraception. 2022. 105: 67-74. PMID: 34407424Journal
Contraception
Study
P1026S
Optimizing Dolutegravir Initiation in Neonates using Population Pharmacokinetic Modeling and Simulation
Citation
Joseph Piscitelli, Mina Nikanjam, Brookie M. Best, Edward Acosta, Mark Mirochnick, Diana F. Clarke, Edmund V. Capparelli, Jeremiah D. Momper. Optimizing Dolutegravir Initiation in Neonates using Population Pharmacokinetic Modeling and Simulation. Journal of Acquired Immune Deficiency Syndromes. 2022. 89: 108-114. PMID: 34629412Journal
Journal of Acquired Immune Deficiency Syndromes
Study
P1026S
Machine Learning Algorithms Using Routinely Collected Data Do Not Adequately Predict Viremia to Inform Targeted Services in Postpartum Women Living With HIV
Citation
Pamela M Murnane, James Ayieko, Eric Vittinghoff, Monica Gandhi, Chaplain Katumbi, Beteniko Milala, Catherine Nakaye, Peter Kanda, Dhayendre Moodley, Mandisa E Nyati, Amy J Loftis, Mary G Fowler, Pat Flynn, Judith S Currier, Craig R Cohen. Machine Learning Algorithms Using Routinely Collected Data Do Not Adequately Predict Viremia to Inform Targeted Services in Postpartum Women Living With HIV. Journal of Acquired Immune Deficiency Syndromes. 2021. 88: 439-447. PMID: 34520443Journal
Journal of Acquired Immune Deficiency Syndromes
Study
1077BF, 1077FF, 1077HS